tetano
Editor, Senior Moderator
Clin Chem Lab Med. 2020 May 12. pii: /j/cclm.ahead-of-print/cclm-2020-0633/cclm-2020-0633.xml. doi: 10.1515/cclm-2020-0633. [Epub ahead of print]
Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations.
Lippi G[SUP]1,[/SUP][SUP]2[/SUP], Adeli K[SUP]1,[/SUP][SUP]3[/SUP], Ferrari M[SUP]1,[/SUP][SUP]4[/SUP], Horvath AR[SUP]1,[/SUP][SUP]5[/SUP], Koch D[SUP]1,[/SUP][SUP]6[/SUP], Sethi S[SUP]1,[/SUP][SUP]7[/SUP], Wang CB[SUP]1,[/SUP][SUP]8[/SUP].
Author information
Abstract
Coronavirus disease 2019 (COVID-19) is the third coronavirus outbreak that has emerged in the past 20 years, after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). One important aspect, highlighted by many global health organizations, is that this novel coronavirus outbreak may be especially hazardous to healthcare personnel, including laboratory professionals. Therefore, the aim of this document, prepared by the COVID-19 taskforce of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), is to provide a set of recommendations, adapted from official documents of international and national health agencies, on biosafety measures for routine clinical chemistry laboratories that operate at biosafety levels 1 (BSL-1; work with agents posing minimal threat to laboratory workers) and 2 (BSL-2; work with agents associated with human disease which pose moderate hazard). We believe that the interim measures proposed in this document for best practice will help minimazing the risk of developing COVID-19 while working in clinical laboratories.
KEYWORDS:
COVID-19; SARS-COV-2; biosafety; coronavirus disease 2019; laboratory
PMID:32396137DOI:10.1515/cclm-2020-0633
Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations.
Lippi G[SUP]1,[/SUP][SUP]2[/SUP], Adeli K[SUP]1,[/SUP][SUP]3[/SUP], Ferrari M[SUP]1,[/SUP][SUP]4[/SUP], Horvath AR[SUP]1,[/SUP][SUP]5[/SUP], Koch D[SUP]1,[/SUP][SUP]6[/SUP], Sethi S[SUP]1,[/SUP][SUP]7[/SUP], Wang CB[SUP]1,[/SUP][SUP]8[/SUP].
Author information
Abstract
Coronavirus disease 2019 (COVID-19) is the third coronavirus outbreak that has emerged in the past 20 years, after severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). One important aspect, highlighted by many global health organizations, is that this novel coronavirus outbreak may be especially hazardous to healthcare personnel, including laboratory professionals. Therefore, the aim of this document, prepared by the COVID-19 taskforce of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), is to provide a set of recommendations, adapted from official documents of international and national health agencies, on biosafety measures for routine clinical chemistry laboratories that operate at biosafety levels 1 (BSL-1; work with agents posing minimal threat to laboratory workers) and 2 (BSL-2; work with agents associated with human disease which pose moderate hazard). We believe that the interim measures proposed in this document for best practice will help minimazing the risk of developing COVID-19 while working in clinical laboratories.
KEYWORDS:
COVID-19; SARS-COV-2; biosafety; coronavirus disease 2019; laboratory
PMID:32396137DOI:10.1515/cclm-2020-0633